Fresenius Kabi introduces cyclophosphamide for injection, a generic substitute for Cytoxan, for use in treating several forms of cancer and minimal change nephrotic syndrome in pediatric patients. Now available in the US, cyclophosphamide for injection, USP, is the newest addition to Fresenius Kabi’s portfolio of generic oncology injectables. The medication is supplied as 500 mg, 1 g, and 2 g single dose vials of lyophilized powder, it can be administered intravenously or orally.